The Arab Drug Company (EGX:ADCI)
Egypt · Delayed Price · Currency is EGP 254.67
-1.52 (-0.59%)
At close: Oct 22, 2026
The Arab Drug Company Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 1,370 | 1,115 | 784.65 | 630.1 | 503.79 |
Other Revenue | - | 2.75 | 0.88 | 3.64 | 1.25 |
| 1,370 | 1,118 | 785.52 | 633.73 | 505.04 | |
Revenue Growth | 22.55% | 42.35% | 23.95% | 25.48% | -5.96% |
Cost of Revenue | 845.35 | 651.9 | 519.53 | 409.39 | 319.61 |
Gross Profit | 524.91 | 466.28 | 265.99 | 224.35 | 185.43 |
Selling, General & Admin | 113.67 | 117.58 | 98.14 | 98.83 | 81.02 |
Other Operating Expenses | 33.54 | 36.82 | 49.75 | 28.44 | 13.64 |
Operating Expenses | 147.21 | 154.41 | 147.89 | 127.27 | 94.66 |
Operating Income | 377.7 | 311.87 | 118.1 | 97.08 | 90.77 |
Interest Expense | -63.43 | -48.57 | -23.09 | -2.32 | -0.95 |
Interest & Investment Income | 8.98 | 19.3 | 27.98 | 1.11 | 1.67 |
Currency Exchange Gain (Loss) | -6.48 | -0.2 | 6.24 | 9.75 | 3.24 |
Other Non Operating Income (Expenses) | 25.76 | 12.41 | 3.17 | 1.11 | 3.05 |
EBT Excluding Unusual Items | 342.53 | 294.8 | 132.4 | 106.73 | 97.78 |
Gain (Loss) on Sale of Assets | - | - | 0.18 | - | 0.51 |
Pretax Income | 342.53 | 294.8 | 132.58 | 106.73 | 98.3 |
Income Tax Expense | 77.82 | 66.95 | 29.75 | 23.96 | 22 |
Net Income | 264.71 | 227.86 | 102.82 | 82.77 | 76.3 |
Preferred Dividends & Other Adjustments | 32.33 | 22.99 | 14.48 | 11.64 | - |
Net Income to Common | 232.38 | 204.86 | 88.35 | 71.13 | 76.3 |
Net Income Growth | 13.43% | 131.89% | 24.21% | -6.78% | -24.76% |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 14 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 14 |
Shares Change | - | - | - | -11.45% | -2.11% |
EPS (Basic) | 19.37 | 17.07 | 7.36 | 5.93 | 5.63 |
EPS (Diluted) | 19.37 | 17.07 | 7.36 | 5.93 | 5.63 |
EPS Growth | 13.43% | 131.89% | 24.21% | 5.28% | -23.14% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 142.51 | -34.63 | -150.22 | 24.33 | -57.04 |
Free Cash Flow Per Share | 11.88 | -2.89 | -12.52 | 2.03 | -4.21 |
Dividend Per Share | 5.000 | 4.167 | 4.175 | 2.250 | 2.400 |
Dividend Growth | 20.00% | -0.20% | 85.56% | -6.25% | -4.00% |
Gross Margin | 38.31% | 41.70% | 33.86% | 35.40% | 36.72% |
Operating Margin | 27.56% | 27.89% | 15.04% | 15.32% | 17.97% |
Profit Margin | 16.96% | 18.32% | 11.25% | 11.22% | 15.11% |
Free Cash Flow Margin | 10.40% | -3.10% | -19.12% | 3.84% | -11.29% |
EBITDA | 416.94 | 338.96 | 120.58 | 99.46 | 100.17 |
EBITDA Margin | 30.43% | 30.31% | 15.35% | 15.69% | 19.83% |
D&A For EBITDA | 39.24 | 27.09 | 2.48 | 2.38 | 9.39 |
EBIT | 377.7 | 311.87 | 118.1 | 97.08 | 90.77 |
EBIT Margin | 27.56% | 27.89% | 15.04% | 15.32% | 17.97% |
Effective Tax Rate | 22.72% | 22.71% | 22.44% | 22.45% | 22.38% |
Revenue as Reported | 1,370 | 1,118 | 785.52 | 633.73 | 505.04 |